We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Epigenomics AG (ECX) NPV

Sell:€0.97 Buy:€1.13 Change: €0.01 (1.03%)
Market closed |  Prices as at close on 26 October 2021 | Switch to live prices |
Change: €0.01 (1.03%)
Market closed |  Prices as at close on 26 October 2021 | Switch to live prices |
Change: €0.01 (1.03%)
Market closed |  Prices as at close on 26 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

Contact details

Geneststrasse 5
+49 (30) 243450

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€12.35 million
Shares in issue:
12.23 million
Frankfurt Stock Exchange

Key personnel

  • Heino.N.F.M von Prondzynski
    Chairman of the Supervisory Board
  • Jorge Garces
    President, Chief Scientific Officer
  • Gregory Hamilton
    Chief Executive Officer
  • Ann Clare Kessler
    Vice Chairwoman of the Supervisory Board
  • Guenther Reiter
    Vice Chairman of the Supervisory Board
  • Noel Doheny
    Chief Executive Officer of Epigenomics Inc.
  • Albert Weber
    Executive Vice President - Finance
  • Nicholas Potter
    Director Reimbursement and Medical Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.